Treatment
Ofatumumab clinical trials
We’re tracking 12 recruiting studies that include Ofatumumab, each written for real people, not researchers, below.
Recruiting studies
- NCT05809986Recruiting
Study of ofatumumab in adults with relapsing multiple sclerosis
This is an observational study (no random treatment) that follows adults with relapsing multiple sclerosis (RMS) who are taking ofatumumab. The study aims to better understand how patients do in real-world care while completing questionnaires and other scheduled check-ins.
AmadoraAges 18–99 - NCT06486779Recruiting
Study of Kesimpta in Greek MS Patients
This study watches how well Kesimpta (ofatumumab) works for people with relapsing multiple sclerosis over time. It collects information from routine doctor visits and scans to see if the treatment is controlling the disease.
Athens, AtticaAges 18–55 - NCT05504694RecruitingPhase 1/Phase 2
Ofatumumab for AQP4-positive NMOSD with recent relapses
This trial studies ofatumumab to reduce disease activity in adults with AQP4-IgG positive NMOSD who have had recent relapses. It may help lower the chance of new attacks and help prevent worsening disability over time.
Xi'an, ShaanxiAges 18 years+ - NCT06867991RecruitingPhase 3
Combination therapy for autoimmune encephalitis
This study tests if combining two medications (a B-cell depleting drug and daratumumab) can help people with autoimmune encephalitis who haven't improved with standard treatments.
Zhengzhou, HenanAges 12 years+ - NCT07353216Recruiting
Testing ofatumumab for relapsing multiple sclerosis
This trial tests if ofatumumab can help people with relapsing multiple sclerosis (RMS) by measuring its effect on nerve damage markers in the blood. It aims to see if the drug is safe and effective for controlling relapses and slowing disease activity.
Guangzhou, GuangdongAges 18 years+ - NCT06167642Enrolling by invitation
Retinal health and nerve markers in MS patients taking ofatumumab
This study looks at how ofatumumab (Kesimpta) affects the back of the eye (retina) and certain nerve proteins in the blood in people with relapsing multiple sclerosis. It may help doctors understand how well the medication is protecting the eyes and nerves.
Baltimore, MarylandAges 18–70 - NCT07779460Recruiting
Comparing two multiple sclerosis medicines in everyday practice
This study compares how well two medicines, Kesimpta and Ocrevus, work for people with multiple sclerosis when used in real life. It looks at patient records to see which treatment might be more effective.
East Hanover, New JerseyAges 18–100 - NCT05344469Recruiting
Testing new MS medicines in people with active relapsing MS
This study tests different approved “disease-modifying” MS medicines (shots and pills) in adults with relapsing multiple sclerosis that is currently active. It mainly looks at outcomes based on how newly starting—or recently started—treatments are handled for people with recent relapses and mild disability.
Albstadt, Baden-WurttembergAges 18–100 - NCT03136146RecruitingPhase 2
Chemo for return or non-responsive blood cancers
This Phase 2 study tests a combination chemotherapy plan for certain leukemia and lymphoma types that have come back or did not respond. It may help shrink or control disease when standard treatment is no longer working.
Houston, TexasAges 15 years+ - NCT05634967Recruiting
Kesimpta pregnancy registry for pregnant people with MS
This registry collects information about pregnancy outcomes in people with multiple sclerosis (MS) who have taken Kesimpta (ofatumumab) during pregnancy or shortly before it. It may help doctors better understand safety and developmental outcomes for babies.
La Jolla, CaliforniaAges 18–100 - NCT07189325RecruitingPhase 3
Comparing two ways to manage relapsing-remitting MS
This trial tests if it's safe to stop or reduce anti-CD20 treatment after several years of stable disease, compared to continuing it. It's for people with relapsing-remitting MS who are at least 40 years old and have had no MS activity for the past 3 years on anti-CD20 therapy.
MontpellierAges 40 years+ - NCT02877303RecruitingPhase 2
Frontline drug treatment for newly diagnosed B-cell leukemia
This trial tests a combination of targeted and chemotherapy medicines as first treatment for newly diagnosed B-cell acute lymphoblastic leukemia (ALL) or related lymphoblastic lymphoma. It aims to improve how well treatment controls the leukemia and how long people can stay in remission.
Houston, TexasAges 14 years+
What Ofatumumab is being studied for
Conditions with recruiting Ofatumumab studies.
Common questions
- Are there clinical trials studying Ofatumumab?
- Yes. Clin2 currently lists 12 recruiting studies that include Ofatumumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Ofatumumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Ofatumumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Ofatumumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.